Thermo Fisher acquires drug trial software firm Clario for up to $9.4bn
PositiveArtificial Intelligence
Thermo Fisher Scientific has made a significant move in the life sciences sector by acquiring Clario, a drug trial data software firm, for up to $9.4 billion. This acquisition is noteworthy as it highlights Thermo Fisher's commitment to enhancing its capabilities in drug development and clinical trials, which could lead to more efficient processes and better outcomes in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System

